Quarterly ResultApr 29, 2026, 07:02 AM
TEVA Q1 Rev $4.0B, +2%; Acquires Emalex Biosciences
AI Summary
Teva Pharmaceutical Industries reported Q1 2026 revenues of ~$4.0 billion, a 2% increase YoY in U.S. dollars, though a 3% decrease in local currency. The company announced the acquisition of Emalex Biosciences, adding an NDA-ready therapy for Tourette syndrome to its neuroscience pipeline, expected to close by Q3 2026. Growth was driven by key innovative brands like AUSTEDO (+41%), AJOVY (+35%), and UZEDY (+62%), while generics revenue declined due to increased competition for lenalidomide capsules. Teva also plans a share repurchase program and maintains its 2026 business outlook, updated for the Emalex transaction.
Key Highlights
- TEVA to acquire Emalex Biosciences, adding NDA-ready therapy for Tourette syndrome; expected to close by Q3 2026.
- Q1 2026 revenues of ~$4.0 billion, up 2% YoY in U.S. dollars, down 3% in local currency.
- GAAP diluted EPS of $0.31; Non-GAAP diluted EPS of $0.53.
- Key innovative brands (AUSTEDO, AJOVY, UZEDY) collectively grew 41% YoY in local currency to $838 million.
- Global generics revenues decreased 16% YoY in local currency, mainly due to lenalidomide competition.
- Biosimilar PONLIMSI™ received FDA approval; biosimilar candidate to Xolair® accepted for review by FDA and EMA.
- Board instructed management to plan for a share repurchase program, subject to approval and market conditions.
- 2026 Business Outlook maintained, with revenues of $16.4 - $16.8 billion, updated for Emalex transaction.